icerguastat   Click here for help

GtoPdb Ligand ID: 13263

Synonyms: IFB-088 | IFB088 | Sephin-1 | Sephin1
Compound class: Synthetic organic
Comment: Icerguastat (IFB-088, Sephin1) selectively inhibits the regulatory subunit PPP1R15A within the PPP1R15A/PP1c phosphatase complex [2]. Inhibiting PPP1R15A results in reduced dephosphorylation of the translation initiation factor eIF2α, which rescues cells from proteostasis collapse. Structurally icerguastat is a guanabenz derivative but it has no α2-adrenerceptor agonist activity. Icerguastat is designed to maintain an active integrated stress response as a cytoprotective mechanism to combat the toxic effects of cellular stress [1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 2
Topological polar surface area 76.76
Molecular weight 196.64
XLogP 1.47
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC(=C(C=C1)Cl)/C=N/N=C(N)N
Isomeric SMILES C1=CC=C(C(=C1)/C=N/N=C(N)N)Cl
InChI InChI=1S/C8H9ClN4/c9-7-4-2-1-3-6(7)5-12-13-8(10)11/h1-5H,(H4,10,11,13)/b12-5+
InChI Key PDWJALXSRRSUHR-LFYBBSHMSA-N
No information available.
Summary of Clinical Use Click here for help
Icerguastat is being developed by InFlectis BioScience as a treatment for amyotrophic lateral sclerosis (ALS). The FDA designated this agent as an orphan drug for ALS in March 2022.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05508074 Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol) Phase 2 Interventional InFlectis BioScience
NCT03610334 A Combined SAD and MAD Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of IFB-088 Phase 1 Interventional InFlectis BioScience